drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous mesothelin-targeted CAR T-cell therapy in which a patient's T cells are lentivirally transduced to express an anti-mesothelin M5 scFv fused to 4-1BB and CD3ζ signaling domains; administered intratumorally (3e6 or 3e7 cells). Binding to mesothelin triggers T-cell activation and costimulation, leading to targeted cytotoxicity and local immune modulation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intratumoral
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express an anti-mesothelin CAR (M5 scFv) with 4-1BB costimulatory and CD3ζ activation domains. Upon binding mesothelin on tumor cells, the CAR triggers T-cell activation, proliferation, and cytotoxic killing, with 4-1BB enhancing persistence; intratumoral delivery promotes localized immune modulation.
drug_name
huCART-meso cells
nct_id_drug_ref
NCT05623488